{"id":"intermediate-dose-thromboprophylaxis","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a dosing strategy rather than a specific drug, employing anticoagulants (typically low-molecular-weight heparins or fondaparinux) at intermediate therapeutic levels to balance thrombotic and bleeding risks. It is commonly used in hospitalized patients, those undergoing surgery, or those with conditions like acute medical illness or cancer where standard prophylactic doses may be insufficient but full therapeutic anticoagulation is not yet indicated.","oneSentence":"Intermediate dose thromboprophylaxis uses anticoagulants at moderate doses to prevent blood clot formation in patients at intermediate risk.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:24.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboembolism prevention in hospitalized patients at intermediate risk"},{"name":"Perioperative thromboprophylaxis in intermediate-risk surgical patients"},{"name":"Thromboembolism prevention in acute medical illness"},{"name":"Cancer-associated thrombosis prevention"}]},"trialDetails":[{"nctId":"NCT06667999","phase":"PHASE4","title":"The Intensive Care Platform Trial","status":"RECRUITING","sponsor":"Anders Perner","startDate":"2025-06-26","conditions":"Intensive Care Patients, Intensive Care Unit Patients, Critical Illness","enrollment":10000},{"nctId":"NCT07384598","phase":"NA","title":"Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.","status":"NOT_YET_RECRUITING","sponsor":"Clinique Saint Pierre Ottignies","startDate":"2026-02-01","conditions":"Thromboprophylaxis, Critical Illness, Intensive Care (ICU)","enrollment":60},{"nctId":"NCT06845423","phase":"PHASE4","title":"Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-05-16","conditions":"Venous Thromboembolism (VTE), Post Partum Women","enrollment":2400},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT06153394","phase":"PHASE3","title":"Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2024-06-01","conditions":"Hepatic Disease, Surgery-Complications, Hypercoagulability","enrollment":50},{"nctId":"NCT03659708","phase":"NA","title":"Pregnancy and Risk of Venous Thromboembolism","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2021-01-22","conditions":"Thromboembolism, Pregnancy","enrollment":600},{"nctId":"NCT04360824","phase":"PHASE4","title":"Covid-19 Associated Coagulopathy","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2020-05-06","conditions":"COVID 19 Associated Coagulopathy","enrollment":176},{"nctId":"NCT05036824","phase":"","title":"Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"University Hospital of Patras","startDate":"2021-10-01","conditions":"Covid19, Hospitalization","enrollment":300},{"nctId":"NCT01727401","phase":"PHASE4","title":"Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia","status":"TERMINATED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Medical Patient, Thrombocytopenia","enrollment":7},{"nctId":"NCT01589393","phase":"NA","title":"OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)","status":"COMPLETED","sponsor":"McMaster University","startDate":"2010-09","conditions":"Traumatic Intracranial Haemorrhage","enrollment":52},{"nctId":"NCT03299296","phase":"PHASE3","title":"Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin","status":"UNKNOWN","sponsor":"Ahmed AbdelMoneim Hassan Ali","startDate":"2017-01-01","conditions":"Thromboses, Deep Vein, Surgery--Complications","enrollment":100},{"nctId":"NCT00634907","phase":"NA","title":"Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)","status":"COMPLETED","sponsor":"Gwen McMillin","startDate":"2006-09","conditions":"Venous Thromboembolism, Bleeding","enrollment":263},{"nctId":"NCT02260908","phase":"NA","title":"OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage - Pilot Study","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2014-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["intermediate dose Enoxaparin"],"phase":"marketed","status":"active","brandName":"Intermediate dose thromboprophylaxis","genericName":"Intermediate dose thromboprophylaxis","companyName":"UMC Utrecht","companyId":"umc-utrecht","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intermediate dose thromboprophylaxis uses anticoagulants at moderate doses to prevent blood clot formation in patients at intermediate risk of thrombotic events. Used for Thromboprophylaxis in intermediate-risk surgical or medical patients, Prevention of venous thromboembolism in hospitalized patients at moderate risk.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}